How we choose factor VIII to treat hemophilia.
@article{Mannucci2012HowWC, title={How we choose factor VIII to treat hemophilia.}, author={P. Mannucci and M. Mancuso and E. Santagostino}, journal={Blood}, year={2012}, volume={119 18}, pages={ 4108-14 } }
In high-income countries, the large availability of coagulation factors for replacement therapy of patients with hemophilia A has raised the life expectancy of these lifelong bleeders to that of males from the general population. The practicing clinician is offered a multitude of choices among several commercial brands of factor VIII extracted from human plasma or engineered from mammalian cell cultures by means of recombinant DNA technology. This article has the goal to offer our opinions on… CONTINUE READING
60 Citations
Recommendations for factor VIII product source to treat patients with haemophilia A.
- Medicine
- Blood transfusion = Trasfusione del sangue
- 2017
- 3
The increased demand for plasma-derived factor VIII in Italy.
- Medicine
- Blood transfusion = Trasfusione del sangue
- 2017
- 5
Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A
- Medicine
- Journal of thrombosis and haemostasis : JTH
- 2016
- 12
Factor VIII products in haemophilia A: one size fits all?
- Medicine
- Thrombosis and haemostasis
- 2015
- 13
- PDF
The inhibitors – a challenge for the management of patients with hereditary haemophilia A
- Medicine
- Romanian journal of internal medicine = Revue roumaine de medecine interne
- 2018
- PDF
2017 Clinical trials update: Innovations in hemophilia therapy
- Medicine
- American journal of hematology
- 2016
- 36
The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A.
- Medicine
- Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
- 2018
- 2
Evolution of the European guidelines for the clinical development of factor VIII products: little progress towards improved patient management
- Medicine
- Haemophilia : the official journal of the World Federation of Hemophilia
- 2013
- 10
References
SHOWING 1-10 OF 75 REFERENCES
Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.
- Medicine
- Blood transfusion = Trasfusione del sangue
- 2010
- 30
Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.
- Medicine
- The New England journal of medicine
- 1990
- 195
Role of von Willebrand factor in immune tolerance induction
- Medicine
- Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
- 2005
- 70
Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
- Medicine
- Blood
- 2001
- 108
- PDF
Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy.
- Medicine
- Transfusion science
- 1998
- 78
Back to the future: a recent history of haemophilia treatment
- Medicine
- Haemophilia : the official journal of the World Federation of Hemophilia
- 2008
- 151
Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors
- Medicine
- Haemophilia : the official journal of the World Federation of Hemophilia
- 2008
- 53
Hemophilia treatment in developing countries: products and protocols.
- Medicine
- Seminars in thrombosis and hemostasis
- 2005
- 26
French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance.
- Medicine
- Thrombosis and haemostasis
- 1998
- 89
Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate.
- Medicine
- Thrombosis and haemostasis
- 1995
- 44